Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix (NASDAQ:CMRX) announced that its Compensation Committee granted inducement stock options to a new employee on March 2, 2025. The award consists of non-statutory stock options to purchase up to 70,000 shares of common stock at an exercise price equal to Chimerix's closing trading price on the grant date.
The stock options have a 10-year term with a four-year vesting schedule: 25% vests on the one-year employment anniversary, with the remaining 75% vesting in equal monthly installments over the following three years. While subject to Chimerix's 2024 Equity Incentive Plan terms, these options were granted outside of it.
Chimerix, a biopharmaceutical company, is developing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
Chimerix (NASDAQ:CMRX) ha annunciato che il suo Comitato per la Compensazione ha concesso opzioni su azioni come indennità a un nuovo dipendente il 2 marzo 2025. L'assegnazione consiste in opzioni su azioni non statutarie per acquistare fino a 70.000 azioni ordinarie a un prezzo di esercizio pari al prezzo di chiusura di Chimerix nel giorno della concessione.
Le opzioni su azioni hanno un termine di 10 anni con un programma di maturazione di quattro anni: il 25% matura al primo anniversario di impiego, mentre il restante 75% matura in rate mensili uguali nei tre anni successivi. Sebbene soggette ai termini del Piano di Incentivazione Azionaria 2024 di Chimerix, queste opzioni sono state concesse al di fuori di esso.
Chimerix, un'azienda biofarmaceutica, sta sviluppando dordaviprone (ONC201) per il glioma mutante H3 K27M e sta conducendo studi di escalation della dose di Fase 1 di ONC206 per valutare la sicurezza e i dati PK.
Chimerix (NASDAQ:CMRX) anunció que su Comité de Compensación otorgó opciones sobre acciones como incentivo a un nuevo empleado el 2 de marzo de 2025. La concesión consiste en opciones sobre acciones no estatutarias para comprar hasta 70,000 acciones ordinarias a un precio de ejercicio igual al precio de cierre de Chimerix en la fecha de concesión.
Las opciones sobre acciones tienen un plazo de 10 años con un calendario de adquisición de cuatro años: el 25% se adquiere en el primer aniversario de empleo, y el 75% restante se adquiere en cuotas mensuales iguales durante los tres años siguientes. Aunque están sujetas a los términos del Plan de Incentivos de Capital 2024 de Chimerix, estas opciones se otorgaron fuera de él.
Chimerix, una empresa biofarmacéutica, está desarrollando dordaviprone (ONC201) para glioma mutante H3 K27M y está llevando a cabo estudios de escalado de dosis de Fase 1 de ONC206 para evaluar la seguridad y los datos de PK.
Chimerix (NASDAQ:CMRX)는 2025년 3월 2일 새로운 직원에게 유인 주식 옵션을 부여했다고 발표했습니다. 이 상은 Chimerix의 부여일 종가와 동일한 행사 가격으로 최대 70,000주를 구매할 수 있는 비법정 주식 옵션으로 구성됩니다.
주식 옵션은 10년의 기간을 가지며, 4년의 베스팅 일정이 있습니다: 1년 근무 기념일에 25%가 베스팅되고, 나머지 75%는 다음 3년 동안 매달 동일한 금액으로 베스팅됩니다. 이 옵션은 Chimerix의 2024년 주식 인센티브 계획의 조건에 따라 부여되었지만, 그 외부에서 부여되었습니다.
Chimerix는 생명공학 제약 회사로, H3 K27M 변이 글리오마를 위한 dordaviprone (ONC201)을 개발하고 있으며, 안전성과 PK 데이터를 평가하기 위해 ONC206의 1상 용량 증가 연구를 진행하고 있습니다.
Chimerix (NASDAQ:CMRX) a annoncé que son Comité de Rémunération a accordé des options d'actions d'incitation à un nouvel employé le 2 mars 2025. L'attribution consiste en des options d'actions non statutaires pour acheter jusqu'à 70 000 actions ordinaires à un prix d'exercice égal au prix de clôture de Chimerix à la date de l'attribution.
Les options d'actions ont une durée de 10 ans avec un calendrier d'acquisition de quatre ans : 25 % s'acquièrent à l'anniversaire de la première année d'emploi, les 75 % restants s'acquièrent par versements mensuels égaux au cours des trois années suivantes. Bien que soumises aux termes du Plan d'Incitation en Actions 2024 de Chimerix, ces options ont été accordées en dehors de celui-ci.
Chimerix, une entreprise biopharmaceutique, développe dordaviprone (ONC201) pour le gliome mutant H3 K27M et réalise des études d'escalade de dose de Phase 1 d'ONC206 pour évaluer la sécurité et les données PK.
Chimerix (NASDAQ:CMRX) gab bekannt, dass sein Vergütungsausschuss am 2. März 2025 einem neuen Mitarbeiter Anreiz-Aktienoptionen gewährt hat. Die Auszeichnung besteht aus nicht-statutären Aktienoptionen zum Kauf von bis zu 70.000 Stammaktien zu einem Ausübungspreis, der dem Schlusskurs von Chimerix am Tag der Gewährung entspricht.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan: 25% werden am ersten Jahrestag der Anstellung fällig, die verbleibenden 75% werden in gleichen monatlichen Raten über die folgenden drei Jahre fällig. Diese Optionen wurden zwar den Bedingungen des Aktienoptionsplans 2024 von Chimerix unterworfen, jedoch außerhalb dieses Plans gewährt.
Chimerix, ein biopharmazeutisches Unternehmen, entwickelt dordaviprone (ONC201) für H3 K27M-mutiertes Gliom und führt Phase-1-Dosiserhöhungsstudien von ONC206 durch, um Sicherheit und PK-Daten zu evaluieren.
- Advancing clinical pipeline with dordaviprone (ONC201) for glioma
- Progress in Phase 1 trials for ONC206
- None.
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 5635(c)(4).
The stock options have an exercise price per share equal to Chimerix’s closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the date of hire and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock options are subject to the terms of Chimerix’s 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
ir@chimerix.com
will@sternir.com
FAQ
What type of stock options did Chimerix (CMRX) grant to its new employee in March 2025?
How long is the vesting period for CMRX's March 2025 inducement stock options?
What is the main clinical development program at Chimerix (CMRX)?
What phase of development is ONC206 currently in at Chimerix?
